BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morimoto H, Morioka H, Imakiire A, Yamamoto R, Hirato T, Sonoda H, Minami K. Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice. Mol Ther Methods Clin Dev 2022;25:534-44. [PMID: 35662814 DOI: 10.1016/j.omtm.2022.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Minami K, Morimoto H, Morioka H, Imakiire A, Kinoshita M, Yamamoto R, Hirato T, Sonoda H. Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses. IJMS 2022;23:11724. [DOI: 10.3390/ijms231911724] [Reference Citation Analysis]
2 Sonoda H, Takahashi K, Minami K, Hirato T, Yamamoto T, So S, Tanizawa K, Schmidt M, Sato Y. Treatment of Neuronopathic Mucopolysaccharidoses with Blood-Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis. Pharmaceutics 2022;14:1240. [PMID: 35745811 DOI: 10.3390/pharmaceutics14061240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]